CS5001 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a **combination regimen** consisting of CS5001 (an investigational antibody-drug conjugate), rituximab (a chimeric monoclonal antibody against CD20), cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline), vincristine (a vinca alkaloid), and prednisone (a synthetic glucocorticoid). CS5001 is under development for treatment of advanced solid tumors and hematologic malignancies, and may be used in combination with classical chemoimmunotherapy regimens. Rituximab binds CD20 on B cells, inducing cell death by complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. Cyclophosphamide leads to DNA cross-linking and apoptosis. Doxorubicin intercalates DNA and inhibits topoisomerase II. Vincristine disrupts microtubule formation and mitosis. Prednisone modulates gene expression impacting lymphoid tissue. This combination is a novel investigational approach potentially targeting B-cell malignancies (like diffuse large B-cell lymphoma, DLBCL, or other non-Hodgkin lymphomas), likely designed to enhance antitumor effect beyond standard regimens such as R-CHOP[1][5][6].